# Efficacy of Sildenafil on the Morbi-mortality of Peripheral Arterial Diseased Patients With Intermittent Claudication

> **NCT02930811** · PHASE3 · WITHDRAWN · sponsor: **University Hospital, Angers**

## Conditions studied

- Peripheral Arterial Occlusive Disease

## Interventions

- **DRUG:** Sildenafil 100 mg oral morning dose
- **DRUG:** Placebo oral morning dose

## Key facts

- **NCT ID:** NCT02930811
- **Lead sponsor:** University Hospital, Angers
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2022-10
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The Investigator-Coordinator has moved to Rennes University Hospital. It will be done under the sponsor of Rennes University Hospital : NCT03686306
- **Last updated:** 2018-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02930811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02930811, "Efficacy of Sildenafil on the Morbi-mortality of Peripheral Arterial Diseased Patients With Intermittent Claudication". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02930811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*